NCT04164069View on ClinicalTrials.gov

Dasatinib for the Prevention of Oxaliplatin-Induced Neuropathy in Patients With Metastatic Gastrointestinal Cancer Receiving FOLFOX Chemotherapy With or Without Bevacizumab

PHASE1CompletedINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

September 2, 2020

Primary Completion Date

June 22, 2023

Study Completion Date

June 22, 2023

Conditions
Advanced Colorectal CarcinomaMetastatic Colorectal CarcinomaStage IV Colorectal Cancer AJCC v8Stage IVA Colorectal Cancer AJCC v8Stage IVB Colorectal Cancer AJCC v8Stage IVC Colorectal Cancer AJCC v8Stage II Colon CancerStage II Rectal CancerStage III Colon CancerStage III Rectal CancerEsophageal CancerPancreatic CancerBile Duct CancerGastric CancerGall Bladder CancerSmall Bowel Adenocarcinoma
Interventions
BIOLOGICAL

Bevacizumab

Given IV

DRUG

Dasatinib

Given PO

DRUG

Fluorouracil

Given IV

DRUG

Leucovorin

Given IV

DRUG

Leucovorin Calcium

Given IV

DRUG

Oxaliplatin

Given IV

OTHER

Quality-of-Life Assessment

Ancillary studies

Trial Locations (1)

43210

Ohio State University Comprehensive Cancer Center, Columbus

All Listed Sponsors
lead

Anne Noonan

OTHER

NCT04164069 - Dasatinib for the Prevention of Oxaliplatin-Induced Neuropathy in Patients With Metastatic Gastrointestinal Cancer Receiving FOLFOX Chemotherapy With or Without Bevacizumab | Biotech Hunter | Biotech Hunter